Total Funding
36
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
212338
Stellar Biotechnologies develops treatments for dermatological and anorectal diseases
Acquired by 
Edesa Biotech
Daniel E. Morse: Director- Kathi Niffenegger: Chief Financial Officer and Corporate Secretary
About the Company
Stellar Biotechnologies, Inc. is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccine pipelines (targeting cancers, immune disorders, Alzheimer's and inflammatory diseases) and for assessing immune system function. KLH can also be used in
immunotoxicology studies for monitoring the immunomodulatory effects of drug candidates.
